Market research
2IV.F 2IV
F EUR Healthcare
Latest close
As of 28 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 452M
- P/E ratio
- 3.05
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -0.17
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- GB00BRS65X63
- Market cap
- 452M
- P/E ratio
- 3.05
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -0.17
About
About 2IV
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Research context
2IV appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 2IV.F discussion.
5 years, 6 months ago
Indivior PLC is currently in a long term uptrend where the price is trading 27.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.
Indivior PLC's total revenue rose by 39.1% to $185M since the same quarter in the previous year.
Its net income has increased by 76.4% to $-13M since the same quarter in the previous year.
Finally, its free cash flow fell by 302.8% to $-73M since the same quarter in the previous year.
Based on the above factors, Indivior PLC gets an overall score of 4/5.